Brain images to predict the effect of drugs
( effective disease-modifying drugs were at hand )Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
DONATE NOW
Your Alzheimer's donation will help billions live without it.
DONATE NOW
New imaging technology
suggests an experimental drug for Alzheimer's reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.
Bapineuzumab -- being developed by Pfizer Inc, Irish drugmaker Elan Corp and Johnson & Johnson -- is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease. Investor confidence in the antibody medicine, however, took a big hit in July 2008 when it failed to meet its main goal in a mid-stage trial and caused brain swelling at higher doses. The new study, which only involved 28 patients, is modest fillip.
"It demonstrated that the drug has an effect on the pathological hallmark of Alzheimer's disease," lead researcher Juha Rinne from Finland's University of Turku told Reuters. Rinne and colleagues used a novel imaging substance called carbon-11-labeled Pittsburgh compound B, which sticks to areas of the brain where there is a lot of beta amyloid plaque. To get more: http://www.postchronicle.com
suggests an experimental drug for Alzheimer's reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.
Bapineuzumab -- being developed by Pfizer Inc, Irish drugmaker Elan Corp and Johnson & Johnson -- is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease. Investor confidence in the antibody medicine, however, took a big hit in July 2008 when it failed to meet its main goal in a mid-stage trial and caused brain swelling at higher doses. The new study, which only involved 28 patients, is modest fillip.
"It demonstrated that the drug has an effect on the pathological hallmark of Alzheimer's disease," lead researcher Juha Rinne from Finland's University of Turku told Reuters. Rinne and colleagues used a novel imaging substance called carbon-11-labeled Pittsburgh compound B, which sticks to areas of the brain where there is a lot of beta amyloid plaque. To get more: http://www.postchronicle.com
The potential brain boosting benefits of omega-3
Increased intakes of the omega-3 fatty acid DHA (docosahexaenonic acid) may improve mental function in middle age people, suggests a new study from the US. ... http://www.nutraingredients.com
No comments:
Post a Comment